



UNITED STATES PATENT AND TRADEMARK OFFICE

ST

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/491,982

01/27/2000

Stephen Shaughnessy

MDSP-P02-180

9313

28120 7590 06/17/2005

FISH & NEAVE IP GROUP
ROPES & GRAY LLP
ONE INTERNATIONAL PLACE
BOSTON, MA 02110-2624

EXAMINER

MERTZ, PREMA MARIA

ART UNIT

PAPER NUMBER

1646

DATE MAILED: 06/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO/ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
--------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

6142005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

See attached.

Prema M Mertz
Primary Examiner
Art Unit: 1646

Art Unit: 1646

Supplemental reasons for allowance:

(1) Upon re-evaluation of the Girasole et al. (1995) and Kishimoto et al. (US Patent No. 5,888,510) references, with respect to the 35 USC 103 rejection of claims 1, 3, 14, 43-49, it would not have been obvious to combine the Girasole and Kishimoto references because Kishimoto et al. disclose administering anti-IL-6 antibodies for treatment of chronic rheumatoid arthritis and suppressing growth of synovial cells and Girasole et al. disclose the effect of IL-11 antibodies on bone marrow and calvarial cells *in vitro*. Therefore, claims 1, 3, 14, 43-49 are not rendered obvious by Girasole et al. and Kishimoto et al. references.

Furthermore, for the reasons cited above, claim 50 is not rendered obvious by Girasole et al. (1995), Kishimoto et al. (US Patent No. 5,888,510) and Queen et al (US Patent No. 5,530,101) references.

(2) Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (571) 272-0829.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

Art Unit: 1646

applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Prema Mertz Ph.D.
Primary Examiner
Art Unit 1646
June 14, 2005